8-K - AMGEN INC (0000318154) (Filer)
Published . Updated .
Key takeaways
- 8-K - AMGEN filed an 8-K with the SEC on Nov 3 (a notice of a material company event).
- Exposed: AMGN
- Market reaction: AMGN +0.9% after three sessions
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
8-K - AMGEN filed an 8-K with the SEC on Nov 3 (a notice of a material company event).
Directly affected
- AMGN Amgen
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR holds the health sector that Amgen belongs to, so it often moves with news about it.
- GILD Gilead Sciences
Gilead Sciences is a peer of Amgen in biological products, (no diagnostic substances); rivals often move on the same news.
- MRNA Moderna
Moderna is a peer of Amgen in biological products, (no diagnostic substances); rivals often move on the same news.
- ARGX argenx SE
argenx SE is a peer of Amgen in biological products, (no diagnostic substances); rivals often move on the same news.
- RVMD Revolution Medicines
Revolution Medicines is a peer of Amgen in biological products, (no diagnostic substances); rivals often move on the same news.
- BIIB Biogen
Biogen is a peer of Amgen in biological products, (no diagnostic substances); rivals often move on the same news.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| AMGN | -2.03% | +1.07% | base | +3.67% | -0.14% | +0.04% | +0.88% |
| XLV | -2.42% | +0.36% | base | +3.08% | +0.65% | +0.47% | +2.39% |
| GILD | -4.93% | +2.07% | base | +4.16% | +0.01% | +0.06% | +1.13% |
| MRNA | -6.29% | -2.97% | base | +13.13% | +5.69% | +15.32% | +17.78% |
| ARGX | -1.09% | -0.93% | base | +3.36% | -0.78% | +2.34% | +6.90% |
| RVMD | -2.84% | -1.45% | base | +2.75% | -8.41% | +0.17% | +3.13% |
| BIIB | -1.90% | +1.86% | base | +2.22% | -2.02% | -0.22% | +2.40% |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Filed: 2026-11-03 AccNo: 0000318154-26-000153 Size: 838 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Source: sec-edgar
Amgen (AMGN) since this story, compared with the market
| Company | When | Move | Status |
|---|---|---|---|
| Amgen (AMGN) | that day | +3.67% | final price |
| Amgen (AMGN) | the next day | -0.14% | final price |
| Amgen (AMGN) | two days later | +0.04% | final price |
| Amgen (AMGN) | three days later | +0.88% | final price |
| Amgen (AMGN) | three days earlier | +1.07% | final price |
| Amgen (AMGN) | five days earlier | -2.03% | final price |
| ARGX | that day | +3.36% | final price |
| ARGX | the next day | -0.78% | final price |
| ARGX | two days later | +2.34% | final price |
| ARGX | three days later | +6.90% | final price |
| ARGX | three days earlier | -0.93% | final price |
| ARGX | five days earlier | -1.09% | final price |
| BIIB | that day | +2.22% | final price |
| BIIB | the next day | -2.02% | final price |
| BIIB | two days later | -0.22% | final price |
| BIIB | three days later | +2.40% | final price |
| BIIB | three days earlier | +1.86% | final price |
| BIIB | five days earlier | -1.90% | final price |
| GILD | that day | +4.16% | final price |
| GILD | the next day | +0.01% | final price |
| GILD | two days later | +0.06% | final price |
| GILD | three days later | +1.13% | final price |
| GILD | three days earlier | +2.07% | final price |
| GILD | five days earlier | -4.93% | final price |
| MRNA | that day | +13.13% | final price |
| MRNA | the next day | +5.69% | final price |
| MRNA | two days later | +15.32% | final price |
| MRNA | three days later | +17.78% | final price |
| MRNA | three days earlier | -2.97% | final price |
| MRNA | five days earlier | -6.29% | final price |
| RVMD | that day | +2.75% | final price |
| RVMD | the next day | -8.41% | final price |
| RVMD | two days later | +0.17% | final price |
| RVMD | three days later | +3.13% | final price |
| RVMD | three days earlier | -1.45% | final price |
| RVMD | five days earlier | -2.84% | final price |
| XLV | that day | +3.08% | final price |
| XLV | the next day | +0.65% | final price |
| XLV | two days later | +0.47% | final price |
| XLV | three days later | +2.39% | final price |
| XLV | three days earlier | +0.36% | final price |
| XLV | five days earlier | -2.42% | final price |
Congressional trades in the stocks in this story
- Sen. Sheldon Whitehouse sold Amgen (AMGN) (held by a spouse), worth $15,001 - $50,000 on 15 Oct 2026. That is 19 days before publication. Filed 2 Nov 2026. View the filing.
- Rep. David J. Taylor bought Amgen (AMGN), worth $1,001 - $15,000 on 22 Sep 2026. That is 42 days before publication. Filed 1 Oct 2026. View the filing.
- Rep. David J. Taylor sold Amgen (AMGN), worth $1,001 - $15,000 on 26 Aug 2026. That is 69 days before publication. Filed 5 Sep 2026. View the filing.
- Rep. Rohit Khanna sold Gilead Sciences (GILD) (held by a dependent child), worth $1,001 - $15,000 on 10 Aug 2026. That is 85 days before publication. Filed 4 Sep 2026. View the filing.
- Rep. Gilbert Cisneros bought Moderna (MRNA), worth $1,001 - $15,000 on 20 Oct 2026. That is 14 days before publication. Filed 10 Nov 2026. View the filing.
- Rep. Maria Elvira Salazar sold Moderna (MRNA), worth $1,001 - $15,000 on 24 Sep 2026. That is 40 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Moderna (MRNA) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 60 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Gilbert Cisneros bought Argenx Se (ARGX), worth $1,001 - $15,000 on 27 Oct 2026. That is 7 days before publication. Filed 10 Nov 2026. View the filing.
- Rep. Gilbert Cisneros bought Argenx Se (ARGX), worth $1,001 - $15,000 on 15 Oct 2026. That is 19 days before publication. Filed 10 Nov 2026. View the filing.
- Rep. Gilbert Cisneros bought Argenx Se (ARGX), worth $15,001 - $50,000 on 14 Oct 2026. That is 20 days before publication. Filed 10 Nov 2026. View the filing.
- Rep. Maria Elvira Salazar sold Biogen (BIIB), worth $1,001 - $15,000 on 24 Sep 2026. That is 40 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Biogen (BIIB) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 60 days before publication. Filed 7 Oct 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who is named in “8-K - AMGEN INC (0000318154) (Filer)”
Companies carried with this story
- AMGN Amgen
Amgen (AMGN) is linked, with no stored direction, high confidence in the 3 Nov 2026 story “8-K - AMGEN INC (0000318154) (Filer).” Reason on file: SEC 8-K filing -> direct issuer disclosure -> AMGN
How “8-K - AMGEN INC (0000318154) (Filer)” reaches Amgen (AMGN)
The 3 Nov 2026 story “8-K - AMGEN INC (0000318154) (Filer)” names Amgen (AMGN) because of this story.
The link for Amgen (AMGN) is this: SEC 8-K filing -> direct issuer disclosure -> AMGN
How strong the case is around Amgen (AMGN)
14 out of 100
“8-K - AMGEN INC (0000318154) (Filer)” scores 14 out of 100. The score uses 1 sources, and 1 linked companies.